199 results
Keyword Busulfan Tillomed Remove keyword
-
List item
Withdrawn application: Doxorubicin Hydrochloride Tillomed
doxorubicin, date of withdrawal: 02/03/2020, Initial authorisation, Last updated: 27/07/2020Doxorubicin Hydrochloride Tillomed: Withdrawn application … Doxorubicin Hydrochloride Tillomed: Withdrawal of the marketing … Doxorubicin hydrochloride Tillomed (doxorubicin hydrochloride … -
List item
Human medicine European public assessment report (EPAR): Busulfan Fresenius Kabi
busulfan, Hematopoietic Stem Cell Transplantation
Date of authorisation: 22/09/2014,
, Revision: 9, Authorised, Last updated: 18/05/2021
Busulfan Fresenius Kabi Cancer Neoplasms Stem … Busulfan Fresenius Kabi … Busulfan Fresenius Kabi, inn Busulfan EMA/195739/2015 EMEA/H/C/002806 … -
List item
Human medicine European public assessment report (EPAR): Busilvex (updated)
busulfan, Hematopoietic Stem Cell Transplantation
Date of authorisation: 09/07/2003, Revision: 20, Withdrawn, Last updated: 27/01/2023Withdrawn busulfan Overview The The approval … Public statement Busilvex (busulfan) Withdrawal of the marketing … authorisation for Busilvex (busulfan) in the European Union (EU … -
List item
Orphan designation: busulfan for: Conditioning treatment prior to haematopoietic-progenitor-cell transplantation
Date of designation: 30/12/2000, Expired, Last updated: 31/07/2013busulfan Overview Please note that … Médicament, France, for busulfan (intravenous use) for the … haematopoietic-progenitor-cell transplantation. Busulfan (intravenous use) has been … -
List item
Referral: Carbamazepin Tillomed
carbamazepin, associated names: Carbamazepin Tillomed, Carbamazepina Tillomed, Karbamazepin Tillomed, Karbamazepina Tillomed, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 30/04/2020, EC decision date: 25/06/2020, Last updated: 21/07/2020Carbamazepin Tillomed … authorisation of Carbamazepin Tillomed (carbamazepine, 200 and 400 … -
List item
Human medicine European public assessment report (EPAR): Trecondi (updated)
Treosulfan, Hematopoietic Stem Cell Transplantation
Date of authorisation: 20/06/2019,
, Revision: 3, Authorised, Last updated: 25/01/2023
at least as effective as busulfan, another medicine used to … with 51% of patients given busulfan (with fludarabine). In an … comparable to those seen with busulfan. Like … -
List item
Human medicine European public assessment report (EPAR): Libmeldy
atidarsagene autotemcel, Leukodystrophy, Metachromatic
Date of authorisation: 17/12/2020,
, , Revision: 5, Authorised, Last updated: 12/09/2022
treatment another medicine, busulfan, is given as a so-called conditioning … conditioning treatment with busulfan, low white cell counts, sometimes … treatment another medicine, busulfan, is given as a so-called conditioning … -
List item
Orphan designation: acetazolamide for: Treatment of periodic paralysis
Date of designation: 21/08/2019, Positive, Last updated: 14/01/2020Commission to Laboratorios Tillomed Spain, S.L.U, Spain, for … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated)
CHMP, Last updated: 27/03/2020Doxorubicin Hydrochloride Tillomed … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2014
CHMP, Last updated: 25/07/2014Busulfan Fresenius Kabi … -
List item
Human medicine European public assessment report (EPAR): Strimvelis
autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34+) cells, Severe Combined Immunodeficiency
Date of authorisation: 26/05/2016,, , Revision: 8, Authorised, Last updated: 01/08/2022
treatment with another medicine, busulfan, to get rid of their abnormal … treatment with another medicine, busulfan, to get rid of their abnormal … -
List item
National expert: Tomasz Grybek, European Medicines Agency (updated)
- Declaration of interests - 80.35 KB | PDF
- Curriculum Vitae - 16.17 KB | PDF
conditioning therapy with Busulfan-based conditioning prior to allogeneic … -
List item
National expert: Sarah Bendahou, National Agency For The Safety Of Medicine And Health Products (updated)
- Declaration of interests - 80.98 KB | PDF
- Curriculum Vitae - 17.22 KB | PDF
Nicotine patch- nicotine pass- busulfan- curacne addictology-oncology-dermat ology 2.3 … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020
CHMP, Last updated: 30/04/2020Carbamazepin Tillomed … -
List item
Orphan designation: Luspatercept for: Treatment of myelofibrosis
Date of designation: 28/02/2020, Positive, Last updated: 18/02/2021the time of designation, busulfan, hydroxycarbamide and ruxolitinib … -
List item
Orphan designation: Imetelstat sodium for: Treatment of myelofibrosis
Date of designation: 14/12/2015, Positive, Last updated: 23/08/2019the time of designation, busulfan, hydroxycarbamide and ruxolitinib … the time of designation, busulfan, hydroxycarbamide and ruxolitinib … -
List item
Orphan designation: N-[(2S)-5-{[(1R, 2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide, bis-tosilate salt for: Treatment of myelofibrosis
Date of designation: 14/10/2016, Positive, Last updated: 15/11/2016the time of designation, busulfan, hydroxycarbamide and ruxolitinib … the time of designation, busulfan, hydroxycarbamide and ruxolitinib … -
List item
Orphan designation: navitoclax for: Treatment of myelofibrosis
Date of designation: 16/12/2019, Positive, Last updated: 25/02/2020the time of designation, busulfan, hydroxycarbamide and ruxolitinib … -
List item
National expert: Antonella Isgrò, Italian Medicines Agency (updated)
- Declaration of interests - 79.78 KB | PDF
- Curriculum Vitae - 26.73 KB | PDF
-
List item
National expert: Simona Jurkovic Mlakar, Agency for medicinal products and medical devices of the Republic of Slovenia (updated)
- Declaration of interests - 79.86 KB | PDF
- Curriculum Vitae - 34.18 KB | PDF
chemotherapy (Treosulfan, Busulfan, etc.) ), in partnership with … -
List item
Orphan designation: 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide monohydrate for: Treatment of myelofibrosis
Date of designation: 28/02/2020, Positive, Last updated: 05/01/2022the time of designation, busulfan, hydroxycarbamide and ruxolitinib … -
List item
Orphan designation: Allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1 (dilanubicel) for: Treatment in haematopoietic stem cell transplantation
Date of designation: 17/01/2018, Withdrawn, Last updated: 22/03/2021cancer medicines such as busulfan to clear the bone marrow … cancer medicines such as busulfan to clear the bone marrow … -
List item
Orphan designation: Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus for: Treatment in haematopoietic stem cell transplantation
Date of designation: 24/03/2020, Positive, Last updated: 07/04/2021cancer medicines such as busulfan to clear the bone marrow … -
List item
Orphan designation: Recombinant human pentraxin-2 for: Treatment of primary myelofibrosis
Date of designation: 19/11/2014, Positive, Last updated: 08/06/2020ruxolitinib, hydroxycarbamide and busulfan were authorised in the EU … ruxolitinib, hydroxycarbamide and busulfan were authorised in the EU … -
List item
Orphan designation: Recombinant human pentraxin-2 for: Treatment of post-essential thrombocythaemia myelofibrosis
Date of designation: 19/11/2014, Positive, Last updated: 08/06/2020ruxolitinib, hydroxycarbamide and busulfan were authorised in the EU … ruxolitinib, hydroxycarbamide and busulfan were authorised in the EU …